Phase-1 of clinical trial for Covaxin begins at AIIMS

On Friday, a 30 year old man was administered the first dose of India’s indigenous COVID vaccine. He became the first person to test the Bharat Biotech’s Covaxin at AIIMS, Delhi

The person was monitored by the doctors at the hospital for two hours and has been discharged. He will be now under medical supervision for next two weeks.

Sanjay Rai, a Professor at the Centre for Community Medicine, AIIMS stated that ”The screening process has been on for voluntary participants who wanted to be enrolled for the first phase of human clinical trial of Covaxin. Of the candidates, 50% were found eligible and we selected this subject to administer the first dose of India’s COVID-19 vaccine at AIIMS, Delhi.”

The vaccine will be administered to other volunteers also from tomorrow onwards. Among the volunteers in the first round, a 60:40 ratio was found (female:male). It was also informed by the doctors that the person who has been administered the vaccine has shown no-immediate side effects.

A Hyderabad-based pharmaceutical company in collaboration with National Institute of Virology and Indian Council of Medical Research has developed the vaccine. ICMR selected AIIMS, Delhi for conducting the trials of Phase I and II.

AIIMS, Delhi is among one of the 12 sites selected to test the vaccine.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s